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The results of the studies presented in this thesis have contributed to a further
understanding of the management of asthma. The two clinical models, nocturnal
airflow limitation and allergen challenge, were very useful to unravel the differences
in pharmacological properties of Fluticasone Propionate (FP) and Salmeterol Xina-
phoate (SLM) and their implications for the clinical setting.
Nocturnal asthma symptoms are a clinical expression of nocturnal airflow limitation
and a circadian variation in Peak Expiratory Flow (PEF) of more than l5olo is
considered to be clinical relevant. This is outlined in chapter 2, where it has been
stated that nocturnal respiratory symptoms are the expression of aschma deterioration,
instead of the separate disease entiry called "nocturnal asthma". Since increase in
nocturnal airflow limitation reflects the natural variability in deterioration of asthma,
it needs therapeutic intervention. Although the optimal therapy strategy is unknown,
(inter)national guidelines recommend addition of long-acting B2-agonists to inhaled
glucocorticosteroids using on a regular base. In chapter 3, we have investigated
different therapy approaches, which are commonly used in asthmatics with nocturnal
airflow limitation. ln 46 atopic asthmatics, all with a circadian PEF variation of
2l5o/o, we have compared 250 p"g bd of FP with 50pg bd of SLM and with the
combination of these both drugs. This was a short-term study of 6 weeks. By using
different lung function tests, all associated with nocturnal airflow limitation, one may
distinguish different therapeutic effects, which can be clinical relevant.The three
treatment approaches showed a comparable therapeutic effect in improving of the
generally used clinical outcome parameters. AII three approaches reduced circadian
PEF variation below l0%o and increased FEV' at day and night above 90olo predicted.
Furthermore, they all decreased PC20 MCh with at least 1.5 doubling concentrations
and dampened the nocturnal decline in PC2s MCh, except for the combination arm.
So far, it seemed that SLM as monotherapy might be as effèctive as FP as monothera-
py and their combination. However, FP and their combination appeared to have
superior beneficial efFects when assessed by PC2o AMP. SLM as monotherapy showed
a less marked improvement in PC2e AMP than when added to FP. Therefore, studies
comparing different treatment approaches and using outcome parameters such as PEF,
FEV, and BHR to direct stimuli like methacholine have to be carefully interpreted.
This study is the first one, which gives support to the formal recommendation as
suggested by (inter)national guidelines.
Nocturnal symptoms, especially nocturnal awakenings, influence daytime cognitive
performance. In chapter 4, we have shown that a high level of circadian PEF varia-
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tion >20o/o was associated with a lower level of daytime cognitive performance in
atopic asthmatics. A battery of psychometric tests was used to assess cognitive
performance. These consisted of Stroop Color \07ord test, Trail making A and B, and
the PASAT rest, assessing focused attention and concentration. Sixteen healthy
volunteers served as control group. In the group of 46 atopic asthmatics significantly
lower scores were observed compared to these healthy volunteers. The cognitive
performance level improved up to the level of the healthy volunteers after 6 weeks
of therapeutic intervention with FP 250p"gbd or SLM 50pg bd or their combination,
no matter which therapy was used. This improvement was accompanied by a mean
reduction in circadian PEF variation to below 10olo. Our results may open a new'way
for investigations since lower daytime cognitive performance, especially in young
children with asthma at school age, may interfere with school- and work perform-
ances. Our findings showed that therapeutic intervention of nocturnal airflow
limitation is imponant to reduce asthma deterioration and to improve the cognitive
function level of asthmatics. Further it seems important to vdidate these findings in
older people with COPD as well.
In chapter 5, we investigated the pathophysiologic implications of inhaled gluco-
corticosteriods (FP) and long-acting B2-agonists (SLM) with respect to their decrease
of bronchial hyperreponsiveness (BHR) to both stimuli, a directly acting one metha-
choline (MCh) and an indirectly acting one i.e. adenosine 5'-monophosphate (AMP).
ThinFfour atopic asthmatics were treated with either FP 2501tgbd or SLM 50pg bd
for 6 weeks. FP resulted in a significantly larger improvement in PC2o AMP
(5tl.lDC, Doubling Concentrations) compared to SLM (2.2+0.9 DC). FP resulted
in a comparable improvement in PC20 MCh (2.2!0.4 DC) compared to SLM
(l 
.4!0.5 DC). FP induced a significantly larger improvement in PCro AMP compared
to PCro MCh (L2.7X1.0 DC), which was less marked for SLM (^0.8+0.7 DC). In
addition to improvement in BHR, both drugs increased comparably the FEVt-values.
Since it has been shown that geometric airway factors are associated with BHR to
MCh, it is intriguing whether improvement in FEVt might lead to a pardal improve-
ment in BHR either assessed with MCh or AMP. In the present study, we observed
only a positive correlation between FP-induced improvement in FEVt and BHR to
MCh. But we observed neither a correlation beween SlM-induced improvement in
FEV, arrd improvement in BHR to MCh, nor between these two drug-induced
improvements in FEVt and improvement in BHR to AMP.
Airway diameter may be improved by different geometric airway factors such as a
decrease of airway wall thickness, which includes reduction of oedema and infiltrating
inflammatory cells, or a reduction of pre-existent airway smooth muscle tone, or a






















































improves the airway diameter by modulation of airway wall oedema, inflammatory
cell infiltration, and pre-existent airway smooth muscle rone as geometric airway
factors in order to improve BHR to MCh. The enhanced FP-induced improvement
in BHR to AMP compared to BHR to MCh, with no positive correlation between
airway diameter and improvement in BHR to AMP, suggests that other mechanisms
are important for its action as well. Therefore, we hypothesize that the improvement
in BHR to AMP by FP seems to be related to reduction in mast cell numbers and
increase in stability of these cells and to a minor or no extenr to airway wall thick-
ness. Since no correlation was observed between SlM-induced increase in FEV, and
improvement in BHR to MCh reduction of pre-existent airway smooth muscle tone
by SLM seems not an important determinant of improvement in BHR to MCh after
SLM use. Furthermore after SLM use, BHR to MCh was improved comparably to
BHR measured with AMP. Both findings strengthen the opinion that SLM has
prolonged bronchoprotective activities based on sustained functional anragonism.
In chapter 6, we introduced a new í32-agonist, picumeterol that was short-acting in
the clinical setting, as assessed by FEV,. This was at odds with their long-acting
activity in in uino and in animal studies. This suggests pecies differences in response
to Br-adrenoceptor stimulation by this compound. The pharmacological properties
of picumeterol being highly potent in increasing intracellular c-AMP, but of apparent-
ly low intrinsic activity. This is, therefore, a picture of a clear partial agonist. The
results of this study showed a clear increase in FEV, and no significant reduction of
BHR to MCh after inhalation of a single dose of picumeterol, which might be due
to this pardal agonism. It is known that an increase in intracellular c-AMP is neces-
sary for airway smooth muscle relaxation and for counteracting bronchospastic
exogenous and endogenous stimuli. Most likely, picumeterol increased intracellular
c-AMP to a level sufficient for increasing FEV,, but insufficienr ro reverse MCh-
induced bronchoconstriction.
Natural allergen exposure, which leads to asthmatic inflammation of the airway wall
is simulated by an allergen challenge in the laboratory. The underlying pathophysiolo-
gic mechanisms are outlined in chapter 7. The early asthmatic response is associated
with release of bronchospastic mediators by lgE-triggered mast cells resulting directly
in airway narrowing and resolving within an hour. This response is followed by a late
asthmatic response within hours which is sustained for more than 12 hours and
associated with an increase in BHR. Naturally occurring diurnal variation in airway
tone may interfere with the detection of the late asthmatic response, thereby dampen-
ing the response. Therefore, a control challenge with saline should always be per-
formed prior to an allergen challenge, in order ro correcr confounders.
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tJTith the introduction of iong-acting Br-agonists, orher pharmacological properties
rvere cnvisaged including anti-inflammatory efÍècts in addition to prolonged broncho-
dilation. This was based on many in zlrro studies and some in uiuo studies, which
wcrc inconclusive as to whethcr the lor-rg-acting Br-agonists have clinically important
anti- inf lammatory propert ies. \We investigated the protective effects of a single dose
of 50pg SLM on the al lergen-induced asrhmaric response in chapter 8. This studv
has shown that SLM completely inhibitcd the Í:rll in FEV, up to l0 hours after the
house dust rnite chal lenge. However, wc performed a control chal lenge ancl appl ied
corrections for confounders, i .e. the bronchodilator properries of SLM and thc
spontaneous diurnal variation in airway c{iameter. After these corrccrions, a biphasic
dampened asthmatic response was observed, and a fal l  in FEV, of more than 20olr
was detected 10 hours after the house dust rnite challenge. Furthermore, SLM
reduced the al lergen-induced increase in BHR 3 hours aÍter chal lenging. but no
reduction was observcd a.frer 24 hours. I t  is clear that a single dose of SLIVI modif les
the early and late asthmatic response, but this is particr.rl:rrly clue to its prolongcci
broncl 'rodi lator and bronchoprotective activi t ics.
In atopic asthmatics, the IgE-mediated allergic response contributes to the asthmatic
inf lan-rrnation of the airway wall .  In this response, T cel ls play a central role. Only
the 'l' cell ar)tigen receptors (l CR) recognize and bind oligopcptide fragments of
allerger-rs accompanied by MHC-class II molecule. f'CR responses to allergcns may
be ol igoclonal, as characterized by use of a l imited set of Vcr and VB gcne famil ics
with conservation of junctional region lengths. \7e ir.rvestigated ir.r chapter 9 the effect
of segrnental rrglveed chalienge on levels of Vo :rnd VB gene expression ancl TCI{
clonal i ty of both blood and BAL f luid I- cel ls, including - l- ,helper and T-suppressor
ceils. At baseline and 24 hours after ragweed challenge, most Vo( and Ví3 gene
famil ies were expressed in a polyclonal manncr, as :rssessed by mult iple TCR
junctionai region lengths using RT-PCR technique and associated with each V gene .
This indicates that the TCR repertoire is diverse in atopic asrhlnarics even afrer
exposrrre of ragweed. Polyclonal char.rges in the TCR rcpertoire of T-helper ar.rcl
T-sr-rppressor cells as answer on ragweed, reflect mechanisrns gove rning T cell recruit-
ment and retention. In contrast, ol igoclonal changes in TCR repertoire were observed
in both 1-helper and T-suppressor cel ls, thus both rypes of T cei ls recognize ragweecl
allergcns. Tire unexpected finding that T-suppressor cells were involved as well in the
Iate asthmatic reaction response could suggest that they rnay provide a beneficial
down-regulatory effect ir.r this rcsponse.
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